STRATA Skin Sciences to Report Third Quarter 2024 Financial Results on November 13, 2024 and Provide Corporate Update
STRATA Skin Sciences (NASDAQ: SSKN), a medical technology company focused on dermatologic treatments, announces its upcoming third quarter 2024 financial results release on November 13, 2024, after market close. Management will host a conference call at 4:30 p.m. ET the same day, including a Q&A session. U.S. participants can dial 1-844-481-2523, while international callers should use 1-412-317-0552. A webcast replay will be available until May 13, 2025, and a telephonic replay until November 20, 2024, using access code 4851779.
STRATA Skin Sciences (NASDAQ: SSKN), un'azienda di tecnologia medicale specializzata in trattamenti dermatologici, annuncia il rilascio dei suoi risultati finanziari del terzo trimestre 2024 previsto per il 13 novembre 2024, dopo la chiusura del mercato. La direzione ospiterà una conferenza telefonica alle 16:30 ET dello stesso giorno, comprensiva di una sessione di domande e risposte. I partecipanti statunitensi possono comporre il numero 1-844-481-2523, mentre i chiamanti internazionali dovrebbero usare il numero 1-412-317-0552. Un replay della webcast sarà disponibile fino al 13 maggio 2025, e un replay telefonico fino al 20 novembre 2024, utilizzando il codice di accesso 4851779.
STRATA Skin Sciences (NASDAQ: SSKN), una empresa de tecnología médica centrada en tratamientos dermatológicos, anuncia el lanzamiento de sus resultados financieros del tercer trimestre de 2024 programado para el 13 de noviembre de 2024, después del cierre del mercado. La dirección llevará a cabo una conferencia telefónica a las 4:30 p.m. ET el mismo día, incluyendo una sesión de preguntas y respuestas. Los participantes de EE. UU. pueden marcar el 1-844-481-2523, mientras que los llamantes internacionales deben usar el 1-412-317-0552. Una repetición de la transmisión en línea estará disponible hasta el 13 de mayo de 2025, y una repetición telefónica hasta el 20 de noviembre de 2024, utilizando el código de acceso 4851779.
STRATA Skin Sciences (NASDAQ: SSKN), 피부과 치료에 집중하는 의료 기술 회사, 2024년 11월 13일 마감 후 2024년 3분기 재무 결과 발표를 예고했습니다. 경영진은 같은 날 오후 4시 30분(동부 표준시)에 전화 회의를 개최하며, 질문 및 답변 세션이 포함됩니다. 미국 참가자는 1-844-481-2523으로 전화할 수 있으며, 국제 전화는 1-412-317-0552를 사용해야 합니다. 웹캐스트 재생은 2025년 5월 13일까지 이용 가능하며, 전화 재생은 2024년 11월 20일까지 이용할 수 있으며, 액세스 코드 4851779를 사용해야 합니다.
STRATA Skin Sciences (NASDAQ: SSKN), une entreprise de technologie médicale axée sur les traitements dermatologiques, annonce la publication de ses résultats financiers du troisième trimestre 2024 prévue le 13 novembre 2024, après la fermeture des marchés. La direction animera une conférence téléphonique à 16h30 ET le même jour, comprenant une session de questions-réponses. Les participants américains peuvent appeler le 1-844-481-2523, tandis que les appelants internationaux doivent composer le 1-412-317-0552. Une rediffusion de la webdiffusion sera disponible jusqu'au 13 mai 2025, et une rediffusion téléphonique jusqu'au 20 novembre 2024, en utilisant le code d'accès 4851779.
STRATA Skin Sciences (NASDAQ: SSKN), ein Medizintechnikunternehmen, das sich auf dermatologische Behandlungen spezialisiert, kündigt die Veröffentlichung seiner Finanzergebnisse des dritten Quartals 2024 für den 13. November 2024 nach Marktschluss an. Das Management wird am selben Tag um 16:30 Uhr ET eine Telefonkonferenz abhalten, einschließlich einer Q&A-Sitzung. US-Teilnehmer können die Nummer 1-844-481-2523 wählen, während internationale Anrufer die 1-412-317-0552 verwenden sollten. Eine Wiederholung des Webcasts wird bis zum 13. Mai 2025 verfügbar sein, und eine telefonische Wiederholung bis zum 20. November 2024 mit dem Zugangscode 4851779.
- None.
- None.
HORSHAM, Pa., Nov. 06, 2024 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces that it will report third quarter 2024 financial results on Wednesday, November 13, 2024 after the market close.
STRATA management will host a conference call at 4:30 p.m. ET on Wednesday, November 13, 2024 to review financial results and provide an update on corporate developments. Following management’s formal remarks, there will be a question-and-answer session.
To listen to the conference call, interested parties within the U.S. should dial 1-844-481-2523 (domestic) or 1-412-317-0552 (international). All callers should dial in approximately 10 minutes prior to the scheduled start time and ask to be joined into the STRATA Skin Sciences, Inc. conference call.
The conference call will also be available through a live webcast that can be accessed at STRATA Skin Sciences 3Q24 Earnings Webcast.
A telephonic replay of the call will be available until November 20, 2024 by dialing 1-877-344-7529 (or 1-412-317-0088 for international callers) and using replay access code 4851779. To access the replay using an international dial-in number, please see here.
A webcast earnings call replay will be available approximately one hour after the live call and remain accessible until May 13, 2025.
About STRATA Skin Sciences, Inc.
STRATA Skin Sciences is a medical technology company dedicated to developing, commercializing, and marketing innovative products for the in-office treatment of various dermatologic conditions, such as psoriasis, vitiligo, and acne. Its products include the XTRAC® excimer laser, VTRAC® lamp systems, and the TheraClear®X Acne Therapy System.
STRATA is proud to offer these exciting technologies in the U.S. through its unique Partnership Program. STRATA’s popular partnership approach includes a fee per treatment cost structure versus an equipment purchase, installation and use of the device, on-site training for practice personnel, service and maintenance of the equipment, dedicated account and customer service associates, and co-op advertising support to help raise awareness and promote the program within the practice.
Safe Harbor
This press release includes "forward-looking statements" within the meaning of the Securities Litigation Reform Act of 1995. These statements include but are not limited to the Company’s plans, objectives, expectations and intentions and may contain words such as “will,” “may,” “seeks,” and “expects,” that suggest future events or trends. These statements, the Company’s ability to launch and sell products recently acquired or to be developed in the future, the Company’s ability to develop social media marketing campaigns, direct to consumer marketing campaigns, and the Company’s ability to build a leading franchise in dermatology and aesthetics, are based on the Company’s current expectations and are inherently subject to significant uncertainties and changes in circumstances. Actual results may differ materially from the Company’s expectations due to financial, economic, business, competitive, market, regulatory, adverse market conditions labor supply shortages, or supply chain interruptions resulting from fiscal, political factors, international conflicts, responses, or conditions affecting the Company, the medical device industry and our customers and patients in general, as well as more specific risks and uncertainties set forth in the Company’s SEC reports on Forms 10-Q and 10-K. Given such uncertainties, any or all these forward-looking statements may prove to be incorrect or unreliable. The statements in this press release are made as of the date of this press release, even if subsequently made available by the Company on its website or otherwise. The Company does not undertake any obligation to update or revise these statements to reflect events or circumstances occurring after the date of this press release. The Company urges investors to carefully review its SEC disclosures available at www.sec.gov and www.strataskinsciences.com.
Investor Contact:
CORE IR
516-222-2560
IR@strataskin.com
FAQ
When will STRATA Skin Sciences (SSKN) report Q3 2024 earnings?
How can I join STRATA Skin Sciences (SSKN) Q3 2024 earnings call?